Document is current
Any future updates will be listed below
-
Authors
Siegel, Joshua S. https://orcid.org/0000-0002-5752-3641
Palanca, Ben J. A.
Ances, Beau M.
Kharasch, Evan D.
Schweiger, Julie A.
Yingling, Michael D.
Snyder, Abraham Z.
Nicol, Ginger E.
Lenze, Eric J.
Farber, Nuri B.
-
Funding
Funding for this research was provided by:
Sidney R. Baer, Jr. Foundation
Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St. Louis
Washington University Institute for Clinical and Translational Research (UL1TR000448)
National Center for Advancing Translational Sciences (UL1TR002345)
National Institute of Mental Health (R25 MH11247)
National Institutes of Health (R01MH118031, R01NR015738, R01AG057680)
- License Information
-
More Information
Article History
Received: 13 August 2020
Accepted: 6 January 2021
First Online: 22 January 2021
Compliance with ethical standards
:
: Author GEN has received research support from NIMH, The Barnes Jewish Hospital Foundation, the Center for Brain Research in Depression, Center for Diabetes Translational Research, Institute for Clinical Translational Science and the McDonnell Center for Systems Neuroscience at Washington University School of Medicine, and has consulted for Alkermes. Author NBF receives research support from the BJH Foundation and holds patents on the use of clonidine to improve the tolerability of ketamine. Author EJL receives grant/research support from NIA, NCCIH, OBSSR, FDA, PCORI, McKnight Brain Research Foundation, Takeda, Alkermes, Aptinyx, Johnson & Johnson, and Lundbeck and previously Roche and the Sidney R. Baer Foundation and he has consulted for Janssen Pharmaceuticals and Jazz Pharmaceuticals. Authors JSS, BJP, BMA, EDK, JAS, AZS, and MDY all report no relevant financial disclosures.
: Study sponsors had no role in study design or conduct, data analysis, interpretation of results, or preparation of the manuscript.
